Up­dat­ed: New Ap­ple Tree biotech emerges with an­ti­bod­ies that might pair with Am­gen, Mi­rati's KRAS drugs

Ap­ple Tree Part­ners is out Mon­day with a new biotech from the labs of NYU Lan­gone Health that aims to tack­le drug re­sis­tance in can­cer.

Aethon Ther­a­peu­tics will get $25 mil­lion from the VC firm, and an­oth­er $5 mil­lion from New York Uni­ver­si­ty and oth­er in­vestors, the New York-based biotech said Mon­day.

The fledg­ling start­up is work­ing off a so-called HapIm­mune im­munother­a­py plat­form from the labs of Shohei Koide and Ben­jamin Neel at NYU’s Perl­mut­ter Can­cer Cen­ter. The two re­searchers be­gan pon­der­ing the idea about three and a half years ago, Neel told End­points News, and they came to Ap­ple Tree’s head of on­col­o­gy Raj Chopra about a year ago to form the com­pa­ny.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER